EUVIMEDEUVIMED entdecken
Crossref

2818-LB: Real-World Evidence on Efficacy and Safety of Semaglutide in Patients with Type 2 Diabetes and Advanced Chronic Kidney Disease

SALMA ELNOUR, ELAMIN ABDELGADIR, FAUZIA RASHID, ALAA KHIDIR, KHADIJA HAFIDH, AZZA KHALIFA, FATHEYA ALAWADI, JALAL NAFACH

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2818-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SALMA ELNOUR und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: GLP-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus (T2DM). However, data on their use in advanced chronic kidney disease (CKD) remain sparse. This study evaluated the safety and efficacy of semaglutide in patients with T2DM and CKD stages 4-5.

Methods

We reviewed 45 patients with T2DM and advanced CKD (stage 4 or 5) who were initiated on semaglutide and followed up for 12 months. Primary endpoints included changes in HbA1c and eGFR from baseline to the last available follow-up. Secondary endpoints included changes in weight, BMI, safety outcomes, and discontinuation rates. Paired analyses were performed using the Wilcoxon signed-rank test, with significance set at p<0.05.

Results

The mean age was 69.1 ± 10.9 years, and 57.8% were female. Baseline HbA1c was 8.3 ± 1.7%, eGFR was 25.5 ± 10.2 mL/min/1.73 m², and weight was 77.6 ± 16.6 kg. Semaglutide significantly reduced HbA1c by 0.71% (p < 0.001), while eGFR remained stable (Δ −0.22, p = 0.305), and weight decreased by −0.43 kg (p = 0.496). The discontinuation rate was 13.3%, mainly due to gastrointestinal adverse events (Figure 1).

Conclusion

The findings of this study suggest that semaglutide is effective for glycemic control and appears to have an acceptable safety profile in advanced CKD, warranting prospective validation. Disclosure S. Elnour: None. E. Abdelgadir: None. F. Rashid: Speaker's Bureau; Current; Novo Nordisk, Boehringer Ingelheim International GmbH, Bayer AG, Novartis AG. A. Khidir: None. K. Hafidh: None. A. Khalifa: None. F. Alawadi: None. J. Nafach: None.

Zitieren

APA

ELNOUR, S., ABDELGADIR, E., RASHID, F., KHIDIR, A., HAFIDH, K., KHALIFA, A., ALAWADI, F., & NAFACH, J. (2026). 2818-LB: Real-World Evidence on Efficacy and Safety of Semaglutide in Patients with Type 2 Diabetes and Advanced Chronic Kidney Disease. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2818-lb

Vancouver

ELNOUR S, ABDELGADIR E, RASHID F, KHIDIR A, HAFIDH K, KHALIFA A, et al. 2818-LB: Real-World Evidence on Efficacy and Safety of Semaglutide in Patients with Type 2 Diabetes and Advanced Chronic Kidney Disease. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2818-lb

BibTeX
@article{ELNOUR2026,
  author = {ELNOUR, SALMA and ABDELGADIR, ELAMIN and RASHID, FAUZIA and KHIDIR, ALAA and HAFIDH, KHADIJA and KHALIFA, AZZA and ALAWADI, FATHEYA and NAFACH, JALAL},
  title = {2818-LB: Real-World Evidence on Efficacy and Safety of Semaglutide in Patients with Type 2 Diabetes and Advanced Chronic Kidney Disease},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2818-lb}
}
Kostenlos starten →